ENTX - Company ID 0001638097
The table below shows Entera Bio Ltd.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $42.00K | $42.00K |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 | $42.00K | $42.00K |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D | $3.20M | $2.25M | $1.64M | $1.52M | $1.12M | $1.48M |
Entera Bio Ltd. reported annual revenue of $42.00K for fiscal year 2025. That is down 76.8% from $181.00K in fiscal 2024. Over the 6 fiscal years shown, annual revenue declined from $365.00K (FY 2020) to $42.00K. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $124.00K |
| $128.00K |
| $122.00K |
| $103.00K |
| $123.00K |
| $62.00K |
| Operating income | -$4.56M | -$3.54M | -$3.26M | -$2.67M | -$2.56M | -$3.02M |
| Income tax | - | - | - | - | - | $0.00 |
| Net income | -$7.31M | -$3.50M | -$3.20M | -$2.66M | -$2.57M | -$3.02M |
| EPS (diluted) | $0.14 | $0.07 | $0.07 | $0.06 | $0.06 | $0.08 |